Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population: An Open-Label, Phase I Study
Common indicators include: Reduced libido and sexual function Persistent fatigue despite adequate sleep Loss of muscle mass and strength Increased abdominal and visceral fat Slower recovery from exercise Mood changes, irritability, or depression Difficulty concentrating or brain fog Decreased motivation Reduced bone density Thinning body or facial hair These symptoms typically develop gradually, which is why many men do not recognize them until they significantly impact quality of life
Costs of medications may not be included depending on plan selection
While these represent uncontrolled single-person reports rather than systematic evidence, they align with the preclinical research findings
All peptides, including PT-141 , must be doctor prescribed and monitored
Vin ung khng mi khng v, d ung